Avo vs OpenEvidence (2026)
Two answers to a clinician's question and they draw on different bodies of evidence. Avo answers from digitised medical society guidelines and calculators, plus whatever protocols the health system adds, which makes every recommendation traceable to a named standard and defensible in a committee. OpenEvidence answers from the current literature through partnerships with major journals and a systematic review publisher, free to verified clinicians and embedded in Epic at named health systems, with more independent evaluation behind it than almost anything else in this index. The difference in failure mode is the useful part. Avo goes wrong when a guideline is superseded and the library has not caught up. OpenEvidence goes wrong when the synthesis reasons past what the cited paper actually supports. Ask each vendor about its own failure rather than the other's.
- Recommendations are anchored to named medical society guidelines, so a clinician and a risk committee can both see exactly what standard the advice came from.
- The record system integration is the deepest in this segment and clears the marketplace credential test rather than resting on partnership language.
- Health systems can add their own protocols to the library, which turns institutional policy into something that reaches the point of care rather than sitting on an intranet.
- The independent literature on this product is deeper than on almost anything else in this index, with a systematic review identifying eleven studies evaluating it between 2024 and 2026.
- Named partnerships with major medical journals and a systematic review publisher put current primary literature behind the answers rather than a guideline snapshot.
- It is free to verified United States clinicians and embedded in Epic at named health systems, so adoption does not depend on a procurement cycle.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Avo and OpenEvidence are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Avo | OpenEvidence |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Reference & Evidence |
| Founded | Not recorded | 2021 |
| Headquarters | Not recorded | Miami, Florida |
| Website | avomd.com | openevidence.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Avo its top capability grade on EHR and Interoperability Depth and Setting and Specialty Coverage. Set against OpenEvidence, Avo grades higher on AI Governance and Bias Disclosure, EHR and Interoperability Depth and Setting and Specialty Coverage. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards OpenEvidence its top capability grade on AI Centrality and Security Certifications and Trust Center. Set against Avo, OpenEvidence grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and HIPAA and BAA Posture. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Avo or OpenEvidence?
On the axes where the AI Health Index separates them, Avo grades higher on AI Governance and Bias Disclosure, EHR and Interoperability Depth and Setting and Specialty Coverage, and OpenEvidence grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and HIPAA and BAA Posture. OpenEvidence leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Avo and OpenEvidence differ most?
The widest separation the AI Health Index records between Avo and OpenEvidence is on AI Governance and Bias Disclosure, where Avo grades B and OpenEvidence grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Avo and OpenEvidence grade the same?
The AI Health Index grades Avo and OpenEvidence the same on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Avo and OpenEvidence not disclosed?
At the last review, at least one of Avo and OpenEvidence published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
OpenEvidence is funded by pharmaceutical and medical device advertising displayed alongside clinical answers, governed by a published advertising policy that is the artifact to read before accepting the arrangement in a clinical setting.
Avo publishes no accuracy figure, model card or evaluation methodology, and its content model carries the opposite exposure: a superseded guideline is wrong for every clinician it reaches until someone notices, and no drift detection concept exists in this segment. Neither vendor publishes an enterprise rate. Both should be asked how their content is reviewed and what triggers a retirement.